Objective: Over 90% of suicide attempters have a psychiatric diagnosis, however twin and family studies suggest that the genetic etiology of suicide attempt (SA) is partially distinct from that of the psychiatric disorders themselves. Here, we present the largest genome-wide association study (GWAS) on suicide attempt using major depressive disorder (MDD), bipolar disorder (BIP) and schizophrenia (SCZ) cohorts from the Psychiatric Genomics Consortium.
Introduction
Suicide is a worldwide public health problem with over 800,000 deaths due to suicide each year (1). It is the second leading cause of death among young adults and rates of suicide are far exceeded by suicide attempts, which occur up to 20 times more frequently (1). This represents a huge personal, social and economic burden, with the Centers for Disease Control and Prevention reporting that suicide costs the US economy $51 billion per year in healthcare and work-loss related costs (2). These stark figures highlight the urgent need for improved prevention and treatment, however progress has been hampered by the lack of reliable methods for predicting suicidality and a poor understanding of its biological etiology.
Over 90% of suicide attempters or victims have a psychiatric disorder, particularly mood disorders, schizophrenia and substance use disorders (3, 4) . Heritability estimates of suicidal behavior from twin studies range from 30-55% and twin and family studies suggest that the genetic etiology of suicide attempt is partially distinct from that of the psychiatric disorders themselves (5, 6) . Several genomewide association studies (GWAS) have been conducted on suicide attempt, by comparing attempters versus non-attempters with depression or bipolar disorder, to test for genetic variants contributing independently to suicide attempt (7) (8) (9) (10) . These studies have failed to identify any replicable genetic associations, likely due to limited sample sizes that were underpowered to detect the genetic effects typical for a single SNP. Other GWAS have examined subjects recruited specifically on the basis of suicide attempt, or suicide attempters and non-attempters from population-based cohorts, but to date no loci have been robustly implicated (11) (12) (13) .
Genetic studies have indicated that suicide attempt has a polygenic architecture, as polygenic risk scores for suicide attempt have shown modest predictive ability in independent samples and small but significant SNP-heritability estimates for suicide attempt have been reported (10, 13) . These findings are consistent with the presence of small genetic effects that the original GWAS were underpowered to detect at genome-wide significance. In the current study, we present the largest GWAS on suicide attempt to date, comparing a total of 6,569 suicide attempters and 17,232 nonattempters, with major depressive disorder (MDD), bipolar disorder (BIP) or schizophrenia (SCZ) from the Psychiatric Genomics Consortium.
Method

Subjects and phenotype definition
Subjects were drawn from 16 MDD cohorts, 21 BIP cohorts and 9 SCZ cohorts in the Psychiatric Genomics Consortium (PGC), where information on suicide attempt (SA) had been collected. Only cases affected with psychiatric disorders were included, and all psychiatric disorders were defined using structured psychiatric interviews according to international consensus criteria (DSM-IV, ICD-9, or ICD-10) ( [14] [15] [16] . Supplementary Tables 1-3 summarise the source, inclusion and exclusion criteria in each cohort. All subjects were of European ancestry. Suicide attempt (SA) was defined in each cohort using items from structured clinical interviews ( Supplementary Table 4 ). Lifetime suicide attempt was defined across cohorts as a deliberate act of self-harm with at least some intent to result in death. Individuals missing information on suicide attempt were excluded. Across the MDD, BIP and SCZ datasets, there were a total of 6,569 suicide attempters and 17,232 non-attempters (Table 1) . All subjects gave written informed consent to participate in the source studies.
Genotyping, quality control and imputation
Cohorts were genotyped following their local protocols, after which standardised quality control and imputation were performed centrally using the PGC 'Ricopili' pipeline (https://sites.google.com/a/broadinstitute.org/ricopili/), for each cohort separately. These procedures have been described in detail previously (17) (18) (19) . Briefly, the quality control parameters for retaining SNPs and subjects were: SNP missingness < 0.05 (before sample removal), subject missingness < 0.02, autosomal heterozygosity deviation (Fhet < 0.2), SNP missingness < 0.02 (after sample removal), difference in SNP missingness between psychiatric cases and healthy controls < 0.02, SNP Hardy-Weinberg equilibrium (P > 10 −10 in psychiatric cases) and minor allele frequency ≥ 0.01.
Genotype imputation was performed using the pre-phasing/ imputation stepwise approach implemented in IMPUTE2/ SHAPEIT (chunk size of 3 Mb and default parameters) to the 1000 Genomes
Project reference panel (20) (21) (22) . SNPs with an imputation INFO-score < 0.6 were excluded. The numbers of SNPs analysed were 8482392, 8807006 and 8814543 in the MDD, BIP, and SCZ datasets respectively.
Statistical analysis
GWAS on suicide attempt were performed using PLINK 1.9 by comparing imputed marker dosages under an additive logistic regression model between suicide attempters and non-attempters in each cohort separately (23) . The first five principal components (PCs), generated using EIGENSTRAT were used as covariates in all GWAS to control for population stratification (24). There was no evidence of stratification artifacts or uncontrolled test statistic inflation in the results from any cohort (e.g. λGC was 0.87 -1.01). Within each psychiatric disorder, meta-analysis was performed using an inverse varianceweighted fixed effects model in METAL, to obtain GWAS results for suicide attempt in MDD, suicide attempt in BIP and suicide attempt in SCZ (25) . A fixed effects meta-analysis was also conducted for a GWAS of suicide attempt in all three psychiatric disorders, in mood disorders only, and for BIP and SCZ.
Polygenic risk scoring was used to investigate the genetic relationship between suicide attempt and the psychiatric disorders and to test for overlap in the genetic etiology of suicide attempt in MDD, BIP and SCZ. PRSice software was used to generate polygenic risk scores (PRS), according to standard protocol (26) . The GWAS results from each discovery study were pruned for linkage disequilibrium (LD) using the P value informed clumping method in PLINK (--clump-p1 1 --clump-p2 1 --clump-r2 0.1 --clump-kb 250). This preferentially retains SNPs with the strongest evidence of association and removes SNPs in LD (r 2 > 0.1) that show weaker evidence of association within 250Kb windows, based on the LD structure in the test dataset. Subsets of SNPs were selected from the results at nine increasingly liberal P value thresholds (P < 0.0001, P < 0.001, P < 0.01, P < 0.05, P < 0.1, P < 0.2, P < 0.3, P < 0.4, P < 0.5). In the test datasets, the SNP probabilities were converted to best-guess data with a genotype call probability cut-off of 0.8. Sets of alleles, weighted by their log odds ratios (OR) from the discovery GWAS, were summed into PRS for each individual in the test datasets using PLINK. The regression model also included five PCs and a covariate for each cohort in the test dataset. The amount of variance explained by the PRS was calculated as Nagelkerke's pseudo-R 2 .
First, PRS for BIP, major depression and SCZ were used to investigate whether genetic liability for psychiatric disorders differs between suicide attempters and non-attempters. To ensure no overlap between the discovery and test datasets, PRS were generated using PGC cohorts not included in the suicide attempt analyses. All cohorts have been described in previous GWAS on the psychiatric disorders conducted by the PGC (17) (18) (19) . For major depression, meta-analyses of PGC cohorts, deCODE, GERA, iPSYCH, Generation Scotland and UK Biobank were available, excluding each of the 16
SA cohorts in turn. The phenotype analysed includes clinically defined MDD cases as well as selfreported MDD symptoms or treatment and is referred to as 'major depression' (17) . These discovery GWAS had approximately 59,000 cases and 112,000 controls. The discovery GWAS for BIP consisted of 11 PGC cohorts totaling 8,711 BIP cases and 15,283 controls, and for SCZ included 25,756 SCZ cases and 35,686 controls from 40 PGC cohorts. The PRS for each psychiatric disorder were tested for association with suicide attempter versus non-attempter status in the same disorder, using the method previously described. Based on the results of these analyses, PRS for major depression were also tested for association with suicide attempt in BIP and SCZ.
Second, the results of the three GWAS on suicide attempt (SA in MDD, SA in BIP and SA in SCZ) were used in turn as discovery studies and the remaining two disorders were used as separate test datasets, to investigate whether PRS for suicide attempt in one disorder are associated with suicide attempt in another. In total, six independent hypotheses were tested using polygenic risk scoring and the Bonferroni corrected significance threshold is 0.008.
The variance in suicide attempt explained by common SNPs (SNP-heritability, ℎ 2 ) was assessed using genomic-relatedness-based restricted maximum-likelihood (GREML), implemented in GCTA software (27) . The SNP probabilities were converted to best-guess data with a genotype call probability cut-off of 0.8. HapMap 3 SNPs with an INFO score ≥ 0.6 were used to calculate the genetic relatedness matrix (GRM) using PLINK 1.9, including individuals with relatedness < 0.05 (23) . Ancestry informative principal components were calculated using GCTA (27) . The GRM was based on a total of 1166347 SNPs in the MDD dataset, 1172705 SNPs in the BIP dataset and 1143070 SNPs in the SCZ dataset. Covariates included 20 PCs calculated using GCTA (because GRM-based analyses are more sensitive to population stratification than polygenic scoring analyses) and a covariate for each cohort within a disorder. The ℎ 2 of SA in each psychiatric disorder was calculated using GCTA (27) .
Power calculations
The Genetic Power Calculator was used to determine the power to detect associations at genomewide significance (P < 5 x 10 -8 ), for the meta-analysis of 6,569 suicide attempters and 17,232 nonattempters across the three psychiatric disorders (28) . This analysis had 78% power to detect an allele with frequency 0.2 and effect size 1.1 at genome-wide significance. From the GCTA-GREML power calculator, the power to detect a ℎ 2 of 20% (approximately half the twin heritability estimate) for suicide attempt was 81%, 92% and 43% in the MDD, BIP and SCZ datasets respectively (29) . The statistical power of polygenic risk scoring was calculated using AVENGEME software (30, 31) . The power of the PRS for the psychiatric disorders to predict SA in same disorder was 51% in BIP, 93% in MDD and 78% in SCZ, given the ℎ 2 for each psychiatric disorder calculated from the summary statistics (20%, 10% and 25% respectively) and hypothesizing a genetic correlation of 0.5 between the psychiatric disorder and suicide attempt. Given a ℎ 2 of 20% for suicide attempt, the power of polygenic risk scores for suicide attempt to detect a significant difference between attempters and non-attempters in the test datasets ranged from 32-64%. The significance threshold for all polygenic risk scoring power calculations was 0.008.
Replication
Genome-wide significant associations with suicide attempt were tested for replication in two independent mood disorder cohorts from the UK Biobank and iPSYCH. The UK Biobank is a populationbased prospective study of 501,726 individuals, recruited at 23 centres across the United Kingdom 
Results
Sample characteristics
The proportion of psychiatric disorder cases reporting suicide attempt ranged from 16% in MDD to 36-37% in bipolar disorder and schizophrenia (Table 1) . For each disorder, there was a higher proportion of females in the suicide attempters than the non-attempters. Table 1 shows the number and proportion of suicide attempters and non-attempters within each psychiatric disorder. The numbers in the individual cohorts are shown in Supplementary Tables 5-7 .
Genome-wide association studies
A GWAS of suicide attempters versus non-attempters was performed in the MDD, BIP and SCZ datasets separately. In the analysis of suicide attempt in MDD, one SNP reached genome-wide significance: rs45593736, P = 2.61 x 10 -8 , OR A allele = 2.38 (Table 2 ). This SNP is in an intron of the ARL5B (ADP-Ribosylation Factor-Like 5B) gene, and the A allele has a frequency of 0.02. In the GWAS of suicide attempt in BIP, an insertion-deletion polymorphism on chromosome 4 met genome-wide significance: chr4_23273116_D, P = 1.15x10 -8 , OR for the deletion = 1.29 (Table 2) . This is an intronic variant in the non-coding RNA LOC105374524. In the analysis of suicide attempt in SCZ, there were no SNPs reaching genome-wide significance, but this analysis had the smallest total sample size.
Meta-analysis of the GWAS results for suicide attempt across all three disorders produced no genomewide significant results ( Supplementary Table 11 ). In a meta-analysis of suicide attempt in mood disorders (MDD and BIP), there were 10 genome-wide significant SNPs from two independent genomic regions (Table 2, Figure 1) . The most significant association was rs138689899 on chromosome 2, P = 2.50 x 10 -8 , OR T allele = 1.75. This is an intergenic SNP that lies between the IWS1
and MYO7B genes. The other significant locus was on chromosome 4 in LOC105374524, as found in the BIP SA analysis. The most significant SNP was rs28591567 (P = 3.11 x 10 -8 , OR G allele = 1.19, frequency G allele = 0.22), in high LD (R 2 = 0.83) with the insertion-deletion polymorphism identified in SA in BIP (Table 2) . Weak evidence for association was found in MDD (rs28591567, P = 0.03, OR allele G allele = 1.11); the locus was not associated with SA in schizophrenia (P = 0.67). No significant associations were identified in the meta-analysis between SA in BIP and SCZ ( Supplementary Table   13 ). 
Replication
SNPs from the three genome-wide significant loci for suicide attempt in the discovery phase were tested for replication in independent mood disorder cohorts from the UK Biobank and iPSYCH. None of these loci showed association with suicide attempt in mood disorders in either study (minimum P value 0.22; Supplementary Table 14 ).
Polygenic risk scoring and SNP-heritability
Polygenic risk scoring was performed to investigate the genetic etiology of suicide attempt in MDD, BIP and SCZ using scores from GWAS on psychiatric disorders and the SA GWAS conducted here. PRS for major depression were significantly associated with suicide attempt in all three disorders (MDDmaximum variance explained (R 2 ) = 0.18%, P = 0.0006; BIP -R 2 = 0.20%, P = 0.0002; SCZ -R 2 = 0.33%, P = 0.0006; Figure 2 ). The PRS for BIP did not differ between suicide attempters and non-attempters with BIP, while PRS for schizophrenia were significantly lower in suicide attempters with schizophrenia compared with non-attempters (R 2 = 0.35%, P = 0.0004, Supplementary Figure 7) .
The SNP heritability (ℎ 2 ) of suicide attempt in each psychiatric disorder was estimated using GREML.
The ℎ 2 estimate of suicide attempt in MDD was 0.03 (SE = 0.03, P = 0.19), in BIP was 0.02 (SE = 0.03, P = 0.25) and in SCZ was 0.10 (SE = 0.07, P = 0.06). None of these ℎ 2 estimates were significantly different from zero. Using these SA GWAS as discovery studies, the polygenic risk scores for SA in one psychiatric disorder were not associated with suicide attempt in another disorder (Supplementary Figure 6 ). log 10 P the UK Biobank and iPSYCH. One possible explanation for this lack of replication is that over 90% of suicide attempters in the replication cohorts had a depression diagnosis, while in the discovery PGC studies, this locus had strongest effect in BIP. In addition, there may be heterogeneity in the definition of suicide attempt, which in the discovery samples was based on psychiatric interviews and in the replication samples was based on self-report questionnaires and hospital records. For the other two loci reaching genome-wide significance for suicide attempt in the discovery phase, statistical power for replication was low, given the effect allele frequency of 2% at each locus.
The within-case analysis strategy utilised in this GWAS was designed to detect associations specific for suicide attempt and was informed by twin and family studies which consistently indicate a genetic component of SA which is distinct from that of the psychiatric disorders themselves (5, 6) . The LOC105374524 association with suicide attempt in mood disorders reported here has not been implicated in major depression, BIP or SCZ in the latest GWAS conducted by the PGC, providing support for this study design (17) (18) (19) .
The polygenic risk scoring analyses showed that suicide attempters with a MDD, BIP or SCZ diagnosis carry a greater liability for major depression than non-attempters. These results indicate the existence of a shared genetic etiology between SA and major depression that is common to suicide attempt in different psychiatric disorders. Clincal studies provide support for these findings, with the presence of depressive symptoms in schizophrenia and increased depressive symptoms in bipolar disorder being risk factors for suicide attempt (35, 36) .
The SNP-heritability estimates for suicide attempt in each disorder were not significantly different from zero and while several twin studies have reported that suicide attempt is moderately heritable, one study found that after adjusting for psychiatric disorders, the heritability decreased from 30% to 17% (5, 37) . Given estimated SNP-heritabilities are generally much lower than twin heritabilities, our samples were underpowered to identify this level of genetic contribution. If this is a more accurate estimate of the independent genetic contribution to suicide attempt, then substantial increases in sample size will be required to fully interrogate the genetic etiology of suicide attempt. Still, the present study is the first consortium-based GWAS on suicide attempt and makes significant progress in increasing numbers by combining samples across clinical cohorts. Further collaborative efforts to amass samples on an even larger scale will be essential to achieve the success seen in GWAS of other psychiatric disorders. Data from population biobanks are now widely available and leveraging these to conduct meta-analyses could rapidly increase statistical power. GWAS comparing suicide attempters versus healthy controls may provide a complementary approach by prioritising loci for follow-up in case-only studies, which should be expanded beyond studies of mood disorders and schizophrenia to also include existing cohorts for other disorders where suicide attempt is prevalent.
The results of GWAS now robustly link hundreds of genetic loci to psychiatric disorders and provide additional opportunities to disentangle genetic effects on suicide attempt from the disorders themselves.
One strength of this study is that samples of suicide attempters have been successfully combined across many individual clinical cohorts. All 46 datasets were processed centrally using the same quality control, imputation and analysis pipeline. Suicide attempt and non-attempt were defined using items from structured psychiatric interviews, although it should be noted that these items vary by interview which could result in heterogeneity in the phenotype definition. Since subjects were not ascertained primarily for suicide attempt, detailed information such as the number of suicide attempts, medical consequences or medication is not available for all participants. This study focused on lifetime suicide attempt to maximize sample size, but some cases who were non-attempters at the time of recruitment may later have attempted suicide.
